Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

@article{Chamberlain2010TemozolomideTL,
  title={Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.},
  author={Marc C Chamberlain},
  journal={Expert review of neurotherapeutics},
  year={2010},
  volume={10 10},
  pages={1537-44}
}
Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset of patients with high-grade gliomas, temozolomide (TMZ; Temodar®, Schering-Plough Pharmaceuticals, NJ, USA) is the primarily palliative treatment for the vast majority of patients. Indeed, for patients with newly diagnosed glioblastoma, the median increase in survival for treatment with TMZ and radiotherapy is only 2.5 months… CONTINUE READING
50 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…